TAO Synergies (TAOX) Cash from Operations (2019 - 2026)
TAO Synergies' (TAOX) quarterly Cash from Operations came in at -$874981.0 in Q2 2026, down 16.81% on a YoY basis from -$1.1 million in Q2 2025, and up 48.01% quarter-over-quarter from -$1.7 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Cash from Operations (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Cash from Operations for 8 consecutive years, with -$874981.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Operations fell 16.81% year-over-year to -$874981.0; the trailing twelve-month figure through Jun 2026 stood at -$6.2 million (down 25.35% YoY), and the FY2025 full-year result was -$6.4 million, down 30.94% from the prior year.
- Cash from Operations advanced to -$874981.0 in Q2 2026 per TAOX's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Cash from Operations topped out at -$749072.0 in Q2 2025 and bottomed at -$3.5 million in Q1 2022.
- Historically, Cash from Operations has averaged -$1.7 million across 5 years, with a median of -$1.5 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 123.86% in 2022, then surged 61.7% in 2023.
- Over 5 years, Cash from Operations stood at -$2.8 million in 2022, then soared by 61.7% to -$1.1 million in 2023, then retreated by 9.56% to -$1.2 million in 2024, then tumbled by 109.85% to -$2.5 million in 2025, then jumped by 64.3% to -$874981.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered -$874981.0, -$1.7 million, and -$2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -270.50 Mn |
| 10 | TAO Synergies | 30.93 Mn | 30.93 Mn | - | -874,981.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -874,981.00 |
| Mar 31, 2026 | -1.68 Mn |
| Dec 31, 2025 | -2.45 Mn |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -749,072.00 |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | -1.17 Mn |
| Sep 30, 2024 | -1.03 Mn |
| Jun 30, 2024 | -853,534.00 |
| Mar 31, 2024 | -1.83 Mn |
| Dec 31, 2023 | -1.07 Mn |
| Sep 30, 2023 | -1.17 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -2.78 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | -2.52 Mn |
| Mar 31, 2022 | -3.49 Mn |
| Dec 31, 2021 | -2.05 Mn |
| Sep 30, 2021 | -1.08 Mn |